Literature DB >> 6166244

Comparison of the effects of arabinosyladenine, arabinosylhypoxanthine, and arabinosyladenine 5'-monophosphate against herpes simplex virus, varicella-zoster virus, and cytomegalovirus with their effects on cellular deoxyribonucleic acid synthesis.

J F Gephart, A M Lerner.   

Abstract

In a single line of human foreskin fibroblasts, minimum inhibitory concentrations (MICs) and the minimum intracellular virus inactivation concentrations (MIICs) of arabinosyladenine, arabinosylhypoxanthine, and arabinosyladenine 5'-monophosphate were assayed for a number of recent isolates of herpes simplex virus types 1 and 2 (HSV-1, HSV-2), varicella-zoster virus (VZV), and cytomegalovirus (CMV). (The term MIIC is used here to describe the selective qualitative intracellular inhibition of the virus inoculum in the primary tissue cultures. The inoculum is not recoverable in subcultures free of antiviral agent.) MICs and MIICs of each of the antiviral agents were readily obtained for each strain of HSV-1, HSV-2, and VZV tested, but all seven strains of CMV tested were much more resistant. At the endpoint, there was little variation in the MICs or MIICs among strans of the same virus. Final MIC results for HSV-1 and HSV-2 were complete after 3 days of incubation; CMV and VZV results required as long as 6 days. The MIC for each herpesvirus increased with incubation, but at the endpoint the MIC and MIIC were approximately equal. VZV was most susceptible to each drug, followed by HSV-1 and HSV-2. The latter two viruses were quite similar. There was no difference in antiviral susceptibilities among any of the strains of HSV-1, HSV-2, VZV, or CMV tested. The toxicities of arabinosyladenine, arabinosylhypoxanthine, and arabinosyladenine 5'-monophosphate were simultaneously compared by using both microscopic cytotoxicity and inhibition of uptakes of [14C]thymidine into cellular deoxyribonucleic acid and of 14C-labeled amino acids into protein. The selective inhibition of each antiviral agent against viral and cellular deoxyribonucleic acid polymerases was confirmed. Simultaneous assays of antiviral and anticellular activities of antiviral agents may be useful in projecting further in vivo experiments.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6166244      PMCID: PMC181377          DOI: 10.1128/AAC.19.1.170

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  Mode of action of 9-beta-D-arabinofuranosyladenine on the synthesis of DNA, RNA, and protein in vivo and in vitro.

Authors:  W E Müller; H J Rohde; R Beyer; A Maidhof; M Lachmann; H Taschner; R K Kahn
Journal:  Cancer Res       Date:  1975-08       Impact factor: 12.701

2.  Effect of adenine arabinoside on cytomegalovirus infections.

Authors:  L T Ch'ien; N J Cannon; R J Whitley; A G Diethelm; W E Dismukes; C W Scott; R A Buchanan; C A Alford
Journal:  J Infect Dis       Date:  1974-07       Impact factor: 5.226

3.  Susceptibility of herpesviruses to three nucleoside analogues and their combinations and enhancement of the antiviral effect of acid pH.

Authors:  M Fiala; A W Chow; K Miyasaki; L B Guze
Journal:  J Infect Dis       Date:  1974-01       Impact factor: 5.226

4.  Purine analogs as potential anticytomegalovirus agents.

Authors:  R W Sidwell; G Arnett; G J Dixon; F M Schabel
Journal:  Proc Soc Exp Biol Med       Date:  1969-09

5.  Effect of adenine arabinoside on severe Herpesvirus hominis infections in man.

Authors:  L T Ch'ien; N J Cannon; L J Charamella; W E Dismukes; R J Whitley; R A Buchanan; C A Alford
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

6.  9-beta-D-arabinofuranosyladenine 5'-phosphate metabolism and excretion in humans.

Authors:  G A LePage; S R Naik; S B Katakkar; A Khaliq
Journal:  Cancer Res       Date:  1975-11       Impact factor: 12.701

7.  The antiviral activity of 9-beta-D-arabinofuranosyladenine (ARA-A).

Authors:  F M Schabel
Journal:  Chemotherapia (Basel)       Date:  1968

8.  Anti-DNA virus activity of the 5'-nucleotide and 3',5'-cyclic nucleotide of 9-beta-D-arabinofuranosyladenine.

Authors:  R W Sidwell; L B Allen; J H Huffman; T A Khwaja; R L Tolman; R K Robins
Journal:  Chemotherapy       Date:  1973       Impact factor: 2.544

9.  The utilization of nucleotides by animal cells.

Authors:  S S Cohen; W Plunkett
Journal:  Ann N Y Acad Sci       Date:  1975-08-08       Impact factor: 5.691

10.  Treatment of herpes simplex virus types 1 and 2 encephalitis in mice with 9-beta-D-arabinofuranosyladenine.

Authors:  B J Sloan; F A Miller; I W McLean
Journal:  Antimicrob Agents Chemother       Date:  1973-01       Impact factor: 5.191

View more
  6 in total

1.  Selective anabolism of 6-methoxypurine arabinoside in varicella-zoster virus-infected cells.

Authors:  K K Biron; P de Miranda; T C Burnette; T A Krenitsky
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

2.  Susceptibility of vaccine strains of varicella-zoster virus to antiviral compounds.

Authors:  S R Preblud; A M Arbeter; E A Proctor; S E Starr; S A Plotkin
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

3.  Nucleic acid hybridization for measurement of effects of antiviral compounds on human cytomegalovirus DNA replication.

Authors:  H Gadler
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

4.  Inhibitory effects of antiherpesviral thymidine analogs against varicella-zoster virus.

Authors:  H Machida; A Kuninaka; H Yoshino
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

5.  Antiviral and antimetabolic activities of neplanocins.

Authors:  E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

Review 6.  Antiviral agents.

Authors:  E D Reines; P A Gross
Journal:  Med Clin North Am       Date:  1988-05       Impact factor: 5.456

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.